HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Humacyte, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$0.40−0.03 (-6.50%)
Close on Oct 19, 2026
- Market cap
- $93.93M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
26.4%
73M of 278M shares
Institutional holders
162
38 new, 33 sold out
Net institutional buying
14M
In Q2 2026
Insider trades, 12 months
5 buys · 2 sales
Net bought $7.39K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Fresenius Medical Care Holdings, Inc. | 18,312,735 | 6.80% | 13D (active) amendment | Jul 10, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of HUMA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 10,107,679 | 3.64% | $7.88M | +2,949,517 | 0.00% |
| ANTIPODES PARTNERS Ltd | 10,103,647 | 3.64% | $7.88M | +4,379,897 | 0.14% |
| Alyeska Investment Group, L.P. | 6,022,925 | 2.17% | $4.70M | New | 0.01% |
| Davidson Kempner Capital Management LP | 5,000,000 | 1.80% | $3.90M | New | 0.05% |
| BlackRock, Inc. | 4,839,929 | 1.74% | $3.78M | −7,477,026 | 0.00% |
| Great Point Partners LLC | 3,750,000 | 1.35% | $2.93M | – | 0.55% |
| UBS Group AG | 2,843,493 | 1.02% | $2.22M | +61,423 | 0.00% |
| Aqr Capital Management LLC | 2,597,134 | 0.93% | $2.03M | +672,443 | 0.00% |
| Geode Capital Management, LLC | 2,185,225 | 0.79% | $1.71M | −1,472,883 | 0.00% |
| Millennium Management LLC | 1,909,049 | 0.69% | $1.49M | +1,800,895 | 0.00% |
| Susquehanna International Group, Llp | 1,699,243 | 0.61% | $1.33M | +641,195 | 0.00% |
| Citadel Advisors LLC | 1,443,376 | 0.52% | $1.13M | New | 0.00% |
| Charles Schwab Investment Management Inc | 1,353,515 | 0.49% | $1.06M | +62,170 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,181,276 | 0.43% | $921.40K | +170,247 | 0.00% |
| Hrt Financial LP | 1,089,508 | 0.39% | $850 | New | 0.00% |
| LPL Financial LLC | 1,025,535 | 0.37% | $800.33K | +161,072 | 0.00% |
| Gsa Capital Partners Llp | 1,005,709 | 0.36% | $785 | +755,853 | 0.05% |
| Private Advisor Group, LLC | 965,091 | 0.35% | $753.16K | +132,292 | 0.00% |
| State Street Corp | 842,537 | 0.30% | $657.52K | −2,201,392 | 0.00% |
| Hbk Investments L P | 790,000 | 0.28% | $616.52K | New | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 162 | 73M | 26.4% | 38 / 56 | 37 / 33 | 32M | 17M |
| Q1 2026 | 159 | 59M | 21.3% | 35 / 54 | 29 / 19 | 25M | 13M |
| Q4 2025 | 147 | 55M | 19.9% | 23 / 54 | 37 / 15 | 13M | 3M |
| Q3 2025 | 141 | 46M | 16.5% | 16 / 41 | 45 / 29 | 3M | 14M |
| Q2 2025 | 156 | 57M | 20.5% | 31 / 72 | 27 / 40 | 17M | 21M |
| Q1 2025 | 168 | 61M | 21.9% | 39 / 57 | 37 / 31 | 24M | 4M |
| Q4 2024 | 162 | 42M | 15.2% | 46 / 53 | 38 / 25 | 11M | 4M |
| Q3 2024 | 143 | 36M | 12.9% | 36 / 53 | 25 / 15 | 16M | 4M |
| Q2 2024 | 123 | 31M | 11.3% | 46 / 50 | 16 / 17 | 15M | 7M |
| Q1 2024 | 95 | 24M | 8.5% | 17 / 29 | 32 / 10 | 8M | 2M |
| Q4 2023 | 88 | 18M | 6.5% | 11 / 35 | 17 / 6 | 2M | 1M |
| Q3 2023 | 83 | 17M | 6.0% | 16 / 38 | 12 / 8 | 3M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of HUMA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 7,716,766 | 2.78% | $6.02M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,122,919 | 0.76% | $1.66M | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,440,479 | 0.52% | $1.12M | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 839,278 | 0.30% | $1.09M | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 835,684 | 0.30% | $1.09M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 728,581 | 0.26% | $947.16K | 0.00% | May 31, 2026 |
| Modern Capital Tactical Income Fund | 589,581 | 0.21% | $460.11K | 0.68% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 474,574 | 0.17% | $616.95K | 0.00% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 415,181 | 0.15% | $271.28K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 276,545 | 0.10% | $359.51K | 0.00% | May 31, 2026 |
| Invesco RAFI US 1500 Small-Mid ETF | 243,339 | 0.09% | $159.00K | 0.01% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 233,838 | 0.08% | $303.99K | 0.00% | May 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 167,033 | 0.06% | $130.35K | 0.00% | Jun 30, 2026 |
| Ultra-Small Company Market Fund | 160,000 | 0.06% | $124.86K | 0.08% | Jun 30, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 136,276 | 0.05% | $106.35K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Laura E. Niklason | President, CEO and Director | 1,392,091 | 0.50% | Jun 12, 2026 |
| Shamik J. Parikh | Chief Medical Officer | 272,713 | 0.10% | May 20, 2026 |
| Dale A. Sander | CFO and Chief Corp. Dev. Off | 307,813 | 0.11% | May 20, 2026 |
| William John Scheessele | Chief Commercial Officer | 22,018 | 0.01% | Apr 15, 2025 |
| Heather Ledbetter Prichard | Chief Operating Officer | 0 | – | Jan 23, 2025 |
| Yang Cao | Chief Regulatory Officer | – | – | Jan 23, 2025 |
| Paul Brian Kuznik | Director | 222,238 | 0.08% | Sep 28, 2026 |
| D. Scott Coward | Director | – | – | Sep 28, 2026 |
| Keith Anthony Jones | Director | 50,000 | 0.02% | Sep 15, 2026 |
| Emery N. Brown | Director | – | – | Jun 12, 2026 |
| Kathleen Sebelius | Director | 148,025 | 0.05% | Jun 12, 2026 |
| Brady W. Dougan | Director | 1,392,091 | 0.50% | Jun 12, 2026 |
| Max N. Wallace | Director | 64,555 | 0.02% | Jun 12, 2026 |
| Susan Richards Windham-Bannister | Director | – | – | Jun 12, 2026 |
| Michael T. Constantino | Director | 43,950 | 0.02% | Jun 12, 2026 |
| Diane Seimetz | Director | – | – | Jun 12, 2026 |
| John Philip Bamforth | Director | – | – | Jun 12, 2026 |
| Charles Bruce Green | Director | 8,400 | 0.00% | Jun 12, 2026 |
| Todd Pope | Director | – | – | Jun 16, 2025 |
| Medical Care Holdings Inc /Ny/ Fresenius | – | 18,312,735 | 6.59% | Dec 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Keith Anthony Jones Director | Sep 14, 2026 | Buy | +10,000 | $0.56 | $5.60K | 50,000 |
| Keith Anthony Jones Director | Aug 20, 2026 | Buy | +10,000 | $0.69 | $6.90K | 40,000 |
| Keith Anthony Jones Director | Aug 17, 2026 | Buy | +30,000 | $0.59 | $17.70K | 30,000 |
| Kathleen Sebelius Director | May 19, 2026 | Buy | +56,818 | $0.88 | $50.00K | 148,025 |
| Michael T. Constantino Director | May 18, 2026 | Buy | +11,000 | $0.89 | $9.79K | 43,950 |
| Dale A. Sander CFO and Chief Corp. Dev. Off | May 18, 2026 | Sale(10b5-1 plan) | −45,887 | $0.90 | $41.30K | 267,213 |
| Shamik J. Parikh Chief Medical Officer | May 18, 2026 | Sale(10b5-1 plan) | −45,887 | $0.90 | $41.30K | 272,713 |
| Dale A. Sander CFO and Chief Corp. Deve. Off. | Nov 16, 2025 | Award | +311,100 | – | – | 313,100 |
| Shamik J. Parikh Chief Medical Officer | Nov 16, 2025 | Award | +311,100 | – | – | 318,600 |
| Brady W. Dougan Director | Aug 20, 2025 | Sale | −591,685 | $1.58 | $934.86K | 0 |
| Laura E. Niklason President, CEO and Director | Aug 20, 2025 | Sale | −591,685 | $1.58 | $934.86K | 0 |
| Brady W. Dougan Director | Aug 19, 2025 | Sale | −1,100,000 | $1.63 | $1.79M | 591,685 |
| Laura E. Niklason President, CEO and Director | Aug 19, 2025 | Sale | −1,100,000 | $1.63 | $1.79M | 591,685 |
| Brady W. Dougan Director | Aug 18, 2025 | Sale | −549,360 | $1.83 | $1.01M | 1,691,685 |
| Laura E. Niklason President, CEO and Director | Aug 18, 2025 | Sale | −549,360 | $1.83 | $1.01M | 1,691,685 |
| William John Scheessele Chief Commercial Officer | Apr 14, 2025 | Buy | +6,493 | $1.54 | $10.00K | 22,018 |
| Dale A. Sander CFO and Chief Corp. Deve. Off. | Apr 10, 2025 | Buy | +20,000 | $1.53 | $30.60K | 40,600 |
| Shamik J. Parikh Chief Medical Officer | Apr 10, 2025 | Buy | +7,500 | $1.55 | $11.63K | 7,500 |
| Charles Bruce Green Director | Apr 8, 2025 | Buy | +6,000 | $1.29 | $7.74K | 8,400 |
| Kathleen Sebelius Director | Apr 8, 2025 | Buy | +50,000 | $1.32 | $66.00K | 91,207 |
| Michael T. Constantino Director | Apr 7, 2025 | Buy | +16,000 | $1.26 | $20.16K | 32,950 |
| Michael T. Constantino Director | Dec 4, 2024 | Buy | +4,600 | $4.39 | $20.19K | 16,950 |
| Brady W. Dougan Director | Nov 20, 2024 | Sale | −261,369 | $4.40 | $1.15M | 1,730,884 |
| Laura E. Niklason President, CEO and Director | Nov 20, 2024 | Sale | −261,369 | $4.40 | $1.15M | 1,730,884 |
| Laura E. Niklason President, CEO and Director | Nov 19, 2024 | Buy | +1,797 | $4.44 | $7.98K | 243,851 |
| Brady W. Dougan Director | Nov 19, 2024 | Buy | +1,797 | $4.44 | $7.98K | 243,851 |
| Brady W. Dougan Director | Nov 19, 2024 | Sale | −427,459 | $4.34 | $1.86M | 1,992,253 |
| Laura E. Niklason President, CEO and Director | Nov 19, 2024 | Sale | −427,459 | $4.34 | $1.86M | 1,992,253 |
| Brady W. Dougan Director | Nov 18, 2024 | Sale | −811,172 | $4.44 | $3.60M | 2,419,712 |
| Laura E. Niklason President, CEO and Director | Nov 18, 2024 | Sale | −811,172 | $4.44 | $3.60M | 2,419,712 |
| Charles Bruce Green Director | Sep 13, 2024 | Option exercise | +1,200 | $4.09 | $4.91K | 2,400 |
| Kathleen Sebelius Director | Sep 10, 2024 | Sale | −3,634 | $5.41 | $19.66K | 40,276 |
| Kathleen Sebelius Director | Sep 10, 2024 | Option exercise | +4,521 | $4.34 | $19.62K | 43,910 |
| Kathleen Sebelius Director | Sep 10, 2024 | Option exercise | +2,479 | $3.35 | $8.30K | 42,755 |
| Kathleen Sebelius Director | Sep 10, 2024 | Sale | −1,548 | $5.39 | $8.34K | 41,207 |
| Brady W. Dougan Director | Sep 10, 2024 | Sale | −288,674 | $5.23 | $1.51M | 3,230,884 |
| Laura E. Niklason President, CEO and Director | Sep 10, 2024 | Sale | −288,674 | $5.23 | $1.51M | 3,230,884 |
| Brady W. Dougan Director | Sep 9, 2024 | Sale | −157,704 | $5.42 | $854.76K | 3,519,558 |
| Laura E. Niklason President, CEO and Director | Sep 9, 2024 | Sale | −157,704 | $5.42 | $854.76K | 3,519,558 |
| Laura E. Niklason President, CEO and Director | Aug 29, 2024 | Buy | +1,222 | $6.55 | $8.00K | 242,054 |
| Brady W. Dougan Director | Aug 29, 2024 | Buy | +1,222 | $6.55 | $8.00K | 242,054 |
| Laura E. Niklason President, CEO and Director | Aug 29, 2024 | Sale | −352,112 | $6.35 | $2.24M | 3,677,262 |
| Brady W. Dougan Director | Aug 29, 2024 | Sale | −352,112 | $6.35 | $2.24M | 3,677,262 |
| Laura E. Niklason President, CEO and Director | Aug 28, 2024 | Sale | −277,090 | $6.47 | $1.79M | 4,029,374 |
| Brady W. Dougan Director | Aug 28, 2024 | Sale | −277,090 | $6.47 | $1.79M | 4,029,374 |
| Dale A. Sander CFO and Chief Corp. Deve. Off. | Aug 27, 2024 | Option exercise | +39,389 | $2.56 | $100.84K | 41,389 |
| Dale A. Sander CFO and Chief Corp. Deve. Off. | Aug 27, 2024 | Sale | −39,389 | $6.68 | $263.12K | 2,000 |
| Laura E. Niklason President, CEO and Director | Aug 27, 2024 | Sale | −252,676 | $6.71 | $1.70M | 4,306,464 |
| Brady W. Dougan Director | Aug 27, 2024 | Sale | −252,676 | $6.71 | $1.70M | 4,306,464 |
| Michael T. Constantino Director | Aug 15, 2024 | Buy | +3,100 | $6.29 | $19.50K | 12,350 |
| Kathleen Sebelius Director | Jun 14, 2024 | Option exercise | +39,389 | $2.56 | $100.84K | 39,389 |
| Brady W. Dougan Director | Jun 12, 2024 | Sale | −271,518 | $7.30 | $1.98M | 4,559,140 |
| Laura E. Niklason President, CEO and Director | Jun 12, 2024 | Sale | −271,518 | $7.30 | $1.98M | 4,559,140 |
| Brady W. Dougan Director | Jun 11, 2024 | Sale | −76,630 | $7.02 | $537.94K | 4,830,658 |
| Brady W. Dougan Director | Jun 11, 2024 | Sale | −282,000 | $7.09 | $2.00M | 4,907,288 |
| Laura E. Niklason President, CEO and Director | Jun 11, 2024 | Sale | −282,000 | $7.09 | $2.00M | 4,907,288 |
| Laura E. Niklason President, CEO and Director | Jun 11, 2024 | Sale | −76,630 | $7.02 | $537.94K | 4,830,658 |
| Brady W. Dougan Director | Jun 4, 2024 | Buy | +2,362 | $6.35 | $15.00K | 240,832 |
| Laura E. Niklason President, CEO and Director | Jun 4, 2024 | Sale | −1,852 | $7.28 | $13.48K | 5,189,288 |
| Brady W. Dougan Director | Jun 4, 2024 | Sale | −1,852 | $7.28 | $13.48K | 5,189,288 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shamik J. Parikh Officer | May 18, 2026 | 45,887 | $41.15K | May 18, 2026 | Restricted Stock Vesting |
| Dale A. Sander Officer | May 18, 2026 | 45,887 | $41.15K | May 18, 2026 | Restricted Stock Vesting |
| Llc Ayabudge Director | Aug 20, 2025 | 591,685 | $936.65K | Aug 20, 2025 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Llc Ayabudge Director | Aug 19, 2025 | 1,100,000 | $1.79M | Aug 19, 2025 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Llc Ayabudge Director | Aug 18, 2025 | 549,360 | $1.00M | Aug 18, 2025 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Llc Ayabudge Director | Nov 20, 2024 | 261,369 | $1.15M | Nov 20, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Llc Ayabudge Director | Nov 19, 2024 | 427,459 | $1.85M | Nov 19, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Llc Ayabudge Director | Nov 18, 2024 | 811,172 | $3.60M | Nov 18, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Kathleen Sebelius Director | Sep 10, 2024 | 5,182 | $28.01K | Sep 10, 2024 | Options Granted - 06/15/2023 |
| Llc Ayabudge Director | Sep 10, 2024 | 288,674 | $1.51M | Sep 10, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Llc Ayabudge Director | Sep 9, 2024 | 157,704 | $855.15K | Sep 9, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES WHEN THE COMPANY WENT PUBLIC VIA SPAC. |
| Llc Ayabudge Director | Aug 29, 2024 | 352,112 | $2.24M | Aug 29, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES VIA SPAC WHEN THE COMPANY WENT PUBLIC IN 2021. |
| LLC Ayabudge Director | Aug 28, 2024 | 277,090 | $1.79M | Aug 28, 2024 | EARLY STAGE INVESTOR IN AHAC. SHARES WERE CONVERTED TO HUMA SHARES VIA SPAC WHEN THE COMPANY WENT PUBLIC IN 2021. |
| LLC Ayabudge Director | Aug 27, 2024 | 252,676 | $1.70M | Aug 27, 2024 | EARLY STAGE INVESTOR IN AHAC. AHAC SHARES WERE CONVERTED TO HUMA SHARES VIA SPAC WHEN THE COMPANY WENT PUBLIC IN 2021. |
| Dale A. Sander Officer | Aug 27, 2024 | 39,389 | $263.31K | Aug 27, 2024 | Options Granted 09/01/2015 |